KRAS MUTATION-RELATED TUMORS
Clinical trials for KRAS MUTATION-RELATED TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS MUTATION-RELATED TUMORS trials appear
Sign up with your email to follow new studies for KRAS MUTATION-RELATED TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-stage study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 26, 2026 09:33 UTC
-
New drug duo targets tough cancers in early trial
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, NEROFE and doxorubicin, in people with advanced solid tumors that have a specific genetic change (KRAS mutation) and a protein called ST2. The goal is to find the best dose and schedule. About 24 adults whose cancer …
Matched conditions: KRAS MUTATION-RELATED TUMORS
Phase: PHASE1 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 22, 2026 13:54 UTC